Blacktrace Holdings Acquires ChemiSens AB Assets
News Feb 20, 2015
Blacktrace Holdings Limited has announced that with effect from 16th January 2015 it has acquired the assets of ChemiSens AB, based in Lund, Sweden. ChemiSens has a 30-year proven track record in the development, manufacture and supply of the highest performance reaction calorimeters.
These sophisticated systems, which will now be supplied and supported via the Syrris brand, perfectly complement the Syrris product range.
Reaction calorimeters are used in a wide range of applications, including carbon capture and sequestration, biological performance, and chemical reaction kinetic and scale-up safety studies.
The combined Syrris and ChemiSens product portfolio - from the straightforward, easy-to-use Atlas Calorimeter to the high performance CPA200 series - allows Syrris to meet customers’ differing needs and applications, whether an introductory or top-end calorimeter is required.
And, with the company’s global presence and the knowledgeable Syrris support team, new and existing customers can be assured of continued worldwide access to professional advice.
Blacktrace is looking forward to working with existing ChemiSens partners, and intends to keep the current structure for the foreseeable future.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Shaken and Stirred: Scaling Up Bioreactors’ Fluid DynamicsNews
By applying analytical techniques often reserved for large-scale industrial bioreactors to smaller lab-based counterparts, researchers are bridging the gap between different ways of mixing biomaterials.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
Highly Potent Active Pharmaceutical Ingredients (HPAPI)
May 21 - May 22, 2018